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Abstract
The critical role of inappropriate inflammation is becoming accepted in many diseases that affect
man, including cardiovascular diseases, inflammatory and autoimmune disorders,
neurodegenerative conditions, infection and cancer.
This review proposes that cancer up-regulates the angiotensin II type 1 (AT1) receptor through
systemic oxidative stress and hypoxia mechanisms, thereby triggering chronic inflammatory
processes to remodel surrounding tissue and subdue the immune system. Based on current
literature and clinical studies on angiotensin receptor inhibitors, the paper concludes that blockade
of the AT1 receptor in synergy with cancer vaccines and anti-inflammatory agents should offer a
therapy to regress most, if not all, solid tumours.
With regard to cancer being a systemic disease, an examination of supporting evidence for a
systemic role of AT1 in relationship to inflammation in disease and injury is presented as a logical
progression. The evidence suggests that regulation of the mutually antagonistic angiotensin II
receptors (AT1 and AT2) is an essential process in the management of inflammation and wound
recovery, and that it is an imbalance in the expression of these receptors that leads to disease.
In consideration of cancer induced immune suppression, it is further postulated that the
inflammation associated with bacterial and viral infections, is also an evolved means of immune
suppression by these pathogens and that the damage caused, although incidental, leads to the
symptoms of disease and, in some cases, death.
It is anticipated that manipulation of the angiotensin system with existing anti-hypertensive drugs
could provide a new approach to the treatment of many of the diseases that afflict mankind.
Review
Tumour and Inflammation
Tumour has been linked with inflammation since 1863,
when Rudolf Virchow discovered leucocytes in neoplastic
tissues and made the first connection between inflamma-
tion and cancer [1]. Since then, chronic inflammation has
been identified as a risk factor for cancer and even as a
means to prognose/diagnose cancer at the onset of the dis-
ease. Examples of such association include the Human
papiloma virus (HPV) and cancer [2], including cervical
[3], cancers of the oesophagus [4] and larynx [5], Helico-
bacter pylori bacterial infection and gastric adenocarci-
noma [6], the hepatitis B virus, cirrhosis and hepato-
cellular carcinoma [7], Schistosoma haematobium and
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cancer of the bladder [8], asbestos induced inflammation
and bronchogenic carcinoma or mesothelioma in
humans [9].
Several reports implicate inflammation as a significant
risk factor in cancer development: asbestos, cigarette
smoke and inflammation of the bowel and pancreas are
but a few well-known examples given [1,10]. These papers
demonstrate that the inflammation environment is one
that would support tumour development and is consist-
ent with that observed in tumour sites. The relationship of
cancer with inflammation is, however, not limited to the
onset of the disease due to chronic inflammation.
Schwartsburd [11] goes a step further and proposes that
chronic inflammation occurs due to tumour environment
stress and that this would generate a protective shield
from the immune system. It has been recently demon-
strated that the tumour microenvironment highly resem-
bles an inflammation site, with significant advantages for
the progression of tumour, including the use of cytokines,
chemokines, leucocytes, lymphocytes and macrophages
to contribute to both vassal dilation and neovascularisa-
tion for increased blood flow, the immunosuppression
associated with the malignant disease, and tumour metas-
tasis [1,11]. Furthermore, this inflammation-site tumour-
generated microenvironment, apart from its significant
role in cancer progression and protection from the
immune system, has a considerable adverse effect to the
success of the various current cancer treatments. It has
recently been demonstrated that the inflammatory
response in cancer can greatly affect the disposition and
compromise the pharmacodynamics of chemotherapeu-
tic agents [12].
It is evident that cancer is using natural inflammatory
processes to spread and, unlikely as it seems at first, it is
proposed that this is through the use of the angiotensin II
type 1 (AT1) receptor.
AT receptors and inflammation
Angiotensin II (Ang II) is a peptide hormone within the
renin-angiotensin system (RAS), generated from the pre-
cursor protein angiotensinogen, by the actions of renin,
angiotensin converting enzyme, chymases and various
carboxy- and amino-peptidases [13]. Ang II is the main
effector of the RAS system, which has been shown to play
an important role in the regulation of vascular homeosta-
sis, with various implications for both cardiovascular dis-
eases and tumour angiogenesis. It exerts its various actions
to the cardiovascular and renal systems via interactions
with its two receptor molecules, angiotensin II type 1
receptor (AT1) and angiotensin II type 2 receptor (AT2)
[13]. AT1 and AT2 receptors have been identified as seven
transmembrane-spanning G protein-coupled receptors
[13], comprising an extracellular, glycosylated region con-
nected to the seven transmembrane α-helices linked by
three intracellular and three extracellular loops. The car-
boxy-terminal domain of the protein is cytoplasmic and it
is a regulatory site. AT1 is 359 amino acids, while AT2 is
363 amino acids being ~30% homologous to AT1 and are
both N-linked glycosylated post-translationally. Various
studies have looked at the pharmacological properties of
the two receptors and the expression of those receptors on
various cell lines. Their affinity for the angiotensin II pep-
tide and their ability to perform their physiological func-
tions has been characterised using radioligand binding
analyses and Scatchard plots. The results have indicated
that both receptors have high binding affinities for the
AngII peptide. The AT1 receptor has demonstrated a Kd of
0.36 nM for the AngII peptide [14], whereas the AT2
receptor has demonstrated a Kd of 0.17 nM respectively,
under similar studies [15].
AT1 receptors are expressed in various parts of the body
and are associated with their respective functions, such as
blood vessels, adrenal cortex, liver, kidney and brain,
while AT2 receptors are highest in fetal mesenchymal tis-
sue, adrenal medulla, uterus and ovarian follicles [13].
The opposing roles of the AT1 and AT2 receptors in main-
taining blood pressure, water and electrolyte homeostasis
are well established. It is, however, becoming recognised
that the renin-angiotensin system is a key mediator of
inflammation [16], with the AT receptors governing the
transcription of pro-inflammatory mediators both in resi-
dent tissue and in infiltrating cells such as macrophages.
In addition to the mediators reviewed by Suzuki et al
(2003) [16], a number of vital molecules in inflammatory
processes are induced by the AT1 receptor. These include
interleukin-1 beta (IL-1b) in activated monocytes [17],
Tumour Necrosis Factor-alpha (TNF-α) [18], Plasmino-
gen Activator Inhibitor Type 1 (PAI-1) [19] and adrenom-
edullin [20] all of which have been shown to have active
participation in various aspects of cancer development.
Activation of AT1 also causes the expression of TGF-β
[21,22] and a review of literature indicates this may be a
unique capability for this receptor. TGF-β is a multifunc-
tional cytokine that is produced by numerous types of
tumours and amongst its many functions is the ability to
promote angiogenesis, tissue invasion, metastasis and
immune suppression [23]. It has been postulated that the
low response rates achieved in cancer patients undergoing
immunotherapy is in part caused by tumour expression of
TGF-β and this is supported by inhibition of the antigen-
presenting functions and anti-tumour activity of dentritic
cell vaccines [24].
On examination of the tumour environment, it is interest-
ing to note that angiotensin II actually increases vasodila-
tion, a phenomenon that researchers have attempted toJournal of Inflammation 2004, 1:3 http://www.journal-inflammation.com/content/1/1/3
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utilise for drug delivery [25]. This would imply something
unusual about the presentation of angiotensin receptors;
however it is predominantly over expression of the vaso-
constrictor AT1 that is reported in association with human
cancers of the breast [26], pancreas [27], kidney [28],
squamous cell carcinoma [29], keratoacanthoma [29], lar-
ynx [30], adrenal gland [30], and lung [31]. AT2 has been
identified as expressed in preference to AT1 in only one
case, in an earlier paper on colorectal cancer [32].
Is it evolution that causes over expression of AT1?
In the 'Hallmarks of Cancer', the authoritative work by
Douglas Hanahan and Robert A. Weinberg, the evolution-
ary acquired capabilities necessary for cancer cells to
become life-threatening tumours are described. Further-
more, it is suggested that cancer researchers should look
not just at the cancer cells, but also at the environment in
which they interact, with cancers eliciting the aid of
fibroblasts, endothelial cells and immune cells [33].
Sustained angiogenesis, tissue invasion and metastasis are
the latter of six necessary steps in tumour progression, as
described in the 'Hallmarks of Cancer' [33]. These envis-
aged evolutionary steps allow cancers to progress from
growths of <2 mm to full tumors. A single evolutionary
step, however, upregulation of AT1 would provide a con-
siderable advantage to cancer cells that have learnt to
evade the apoptosis and growth regulatory effects of TGF-
β. Supporting this hypothesis is the observed genetic
change from non-invasive cancer esophageal cell line T.Tn
to invasive cancer cell line T.Tn-AT1. This genetic change
concerns 9 genes, all of which are known to influence
inflammation signalling (8 down and 1 up regulated)
[34].
Is it environment?
The alternative basis under which induction of AT1 in
tumours may occur is by looking at the environment
under which the cancer is developing. Stresses and cell
damage on the growing tumour boundary could poten-
tially be causing the expression of AT1. Evidence that
appears to support this view can be found in a study of
AT1 expression in breast cancers [35]. In this case, in situ
carcinoma has over-expressed AT1 receptors in addition
to expressing proteins for yet more AT1. In the invasive
carcinoma, high proportions of AT1 receptors are found
on the tumour boundary, but in this case protein genera-
tion for AT1 is very noticeably absent. How could this
behaviour be explained? Perhaps the answer lies in oxida-
tive stress and hypoxia.
The formation of oxidised LDL by monocytes and macro-
phages at the sites of tissue damage has been established
in a recent report by Jawahar L. Mehta and Dayuan Li [36].
In this study, the ox-LDL LOX-1 receptor is noted to be
induced by fluid shear stress (4 hrs), TNF-α (8 hrs) and
self-induced by ox-LDL (12 hrs). Of particular interest is
that activation of LOX-1 by ox-LDL induces the expression
of the AT1 receptor [36]. This key role of ox-LDL regarding
AT1 is demonstrated by HMG Co-A reductase inhibitor
causing the down-regulation of the AT1 receptor with con-
sequential reduction in inflammatory response [37]. Also
of interest is that another marker of many diseases, homo-
cysteine, enhances endothelial LOX-1 expression [38].
Hypoxia has been demonstrated to induce the expression
of both AT1b (AT1a and AT1b are subsets of AT1) and AT2
receptors in the rat carotid body and pancreas [39,40]. The
expression of AT1 and AT2 receptors has been studied
during the development and regression of hypoxic pul-
monary hypertension [41]. Hypoxia has been shown to
strongly induce the expression of AT1b but not AT1a. The
expression of AT2 is believed to protect the cell from
apoptosis and this effect has been demonstrated in the
brain when AT1 is antagonized [42]. Since HIF-1α gov-
erns many hypoxia driven transcriptions [43], its control
of AT1b and AT2 expression can be hypothesized. AT1
activation has also been shown to increase the activity of
HIF-1α [43], and is consistent with other cases of AT1 pro-
viding a positive feedback mechanism. Since hypoxia
counts for the expression of AT1b, the speculation that the
AT1a subtype is induced by oxidative stress is tempting,
although a review of literature appears absent in this
regard and further investigation is required to confirm this
hypothesis.
A review of hypoxia and oxidative stress in breast cancer
cites the chaotic flow of blood in the tumor environment
with resultant periods of hypoxia and reperfusion [44].
Reperfusion after myocardial infarction or cerebral
ischemia is known to cause the generation of ROS. Hence,
summarised in figure 1, the tumor environment thus
offers both hypoxia and oxidative stress mechanisms for
induction of AT1. It would however seem likely that
genetic factors speed up the progression of the more
aggressive forms of cancer.
A combination therapy for cancer
The evidence relating to over-expression of AT1 with can-
cer progression is compelling. To this effect, AT1 blockade
has been hypothesised as the mechanism to overcome
cancer associated complications in organ graft recipients
[45]. Additionally, a study undertaken in 1998 suggested
that hypertensive patients taking ACE inhibitors were sig-
nificantly less at risk of developing cancer than those tak-
ing other hypertensive treatments [46].
Tumour progression has been significantly slowed with
AT1 receptor antagonists [47,48]. The results appeared to
far exceed the expectations of simple inhibition ofJournal of Inflammation 2004, 1:3 http://www.journal-inflammation.com/content/1/1/3
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angiogenesis. Reduction of MCP-1 was noted [48], as was
the expression of many pro-inflammatory cytokines. The
activity of tumour-associated macrophages was also
noticed to be severely impaired [48]. The importance in
reducing the action of tumour-associated macrophages in
extracellular matrix decomposition is not to be underesti-
mated, since, in this action, they further progress remod-
elling by releasing stored TGF-β [49]. The similarity of
action of tumour associated macrophages with those in
the tissue healing and repair environment has been noted
[49]. The tumour suppressant action of tranilast, an AT1
antagonist, [50] has been more widely explored [51-54].
In one study on the inhibition of uterine leiomyoma cells,
Tranilast also induced p21 and p53 [55]. Similarly, the
AT1 blocker losartan has been shown to antagonise plate-
lets, which are thought to modulate cell plasticity and
angiogenesis via the vascular endothelial growth factor
(VEGF) [56]. It has been postulated that losartan and
other AT1 blockers can act as novel anti-angiogenic, anti-
invasive and anti-growth agents against neoplastic tissue
[56]. Furthermore, it has been shown that angiotensin II
induces the phosphorylations of mitogen-activated pro-
tein kinase (MAPK) and signal transducer and activator of
transcription 3 (STAT3) in prostate cancer cells. In con-
trast, AT1 inhibitors have been shown to inhibit the pro-
liferation of prostate cancer cells stimulated with EGF or
angiotensin II, through the suppression of MAPK or
STAT3 phosphorylation [57]. Angiotensin II also induces
(VEGF), which plays a pivotal role in tumour angiogen-
esis and has been the target of various therapeutics,
including antibodies and aptamers [58]. Although the
role of angiotensin II in VEGF-mediated tumour develop-
ment has not yet been elucidated, an ACE inhibitor signif-
icantly attenuated VEGF-mediated tumour development,
AT1 expression in cancer Figure 1
AT1 expression in cancer. A cycle of oxidative stress (enhanced by homocysteine and ox-LDL) and hypoxia on the growing 
tumour boundary co-operatively promotes AT1 expression, leading to inflammation-associated angiogenesis, invasion, metas-
tasis and immune suppression.Journal of Inflammation 2004, 1:3 http://www.journal-inflammation.com/content/1/1/3
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accompanying the suppression of neovascularisation in
the tumour and VEGF-induced endothelial cell migration
[59]. Perindopril, another ACE inhibitor has also been
shown to be a potent inhibitor of tumour development
and angiogenesis through suppression of the VEGF and
the endothelial cell tubule formation [60].
The powerful direct and indirect suppression effects of
TNF-α [61], IL-1β [62] and TGF-β [63] on APC presenting
cells, NK, T and B cell have been reviewed [64]. The
expression of these mediators makes an effective immune
response most unlikely.
Despite this, it has long been established that the body
does have the capability to recognise cancer cells and
develop antigens. Dentritic cell vaccines for instance have
been developed and have demonstrated limited effect in
treating established tumours. The effectiveness of one
such approach was greatly enhanced leading to complete
regression of tumours in 40% of cases when TGF-β was
neutralised using TGF-β monoclonal antibodies in syn-
ergy with a dentritic cell vaccine [24].
Strong evidence suggests that tumour cells over-express
AT1 receptors and compelling evidence has been pre-
sented on the implications of AT1 in cancer progression.
Although still at a theoretical stage, this evidence leads to
the formulation of the hypothesis that effective blockade
of AT1 with a tight binding receptor antagonist, in combi-
nation with NSAIDs to further control the inflammation,
and immunotherapy, such as cancer vaccines, would pro-
vide an effective treatment. Most, if not all, solid tumours
utilise inflammation processes, which, through the over-
expression and activation of AT1 and the subsequent
expression of a number of inflammatory cytokines and
chemokines, allow for tumour protection from the
immune system through immunosuppression, as well as
tumour progression and metastasis. Blocking these path-
ways through inhibition of AT1 using one of the commer-
cially available AT1 inhibitors, whilst lifting the induced
protective effect of immunosuppression and further
reducing inflammation with the use of NSAIDs will both
inhibit tumour progression and allow currently devel-
oped immunotherapies, such as cancer vaccines, to pro-
mote their therapeutic effect uninhibited. The role of AT1
post-metastasis, given the observation that AT1 protein
expression ceases, as demonstrated in the breast cancer
study, requires further investigation [35]. However, the
premise for the necessity of immunosuppression by can-
cer is none the less fundamental and this is encouraging
for the prospects of regression of cancers that have pro-
gressed to metastasis by combinational AT1 blockade/
immune therapy.
Learning from Cancer: wound management
Cancer is a systemic disease, one that can affect every part
and organ in the body and, as presented in this review so
far with regards to the role of AT1 in cancer, AT1 upregu-
lation is of the utmost importance in the activation of
inflammation. Systemically, therefore, what purpose does
this upregulation of AT1 serve? The release of ACE and
extended expression of AT1 and AT2 during the healing
process following vascular injury helps to answer this
question [65]. AngII is demonstrated to promote migra-
tion and proliferation of smooth muscle cells, as well as
production of extracellular matrix through AT1 activation.
In this work [65], the AT1 and AT2 receptors are recog-
nized as having a substantial role in the tissue repair and
healing processes of injured arteries. Although further lit-
erature in regard to the role of AT1 and AT2 in the healing
process appears absent and additional studies are
required, it appears rational that a systemic agent for the
management of inflammation and healing would be one
associated with the vascular system.
The activation of AT1 (shown in figure 2) has a powerful
pro-inflammatory effect [16], promoting the expression
of many pro-inflammatory mediators, such as cytokines,
chemokines and adhesion molecules through the activa-
tion of signalling pathways. The influx, proliferation and
behaviour of immune cells are steered away from an effec-
tive immune response to pathogens (thereby achieving
immunosuppression) but instead towards activities con-
sistent with a wound environment. Through the activa-
tion of these pathways [16], AT1 effectively elicits this
response with local effects intended to initiate wound
recovery through destruction of damaged cells, remodel-
ling, the laying down of fibrous material and angiogen-
esis. AT1 acts in three ways, as indicated in figure 3. Firstly,
via the up-regulation of growth factors that leads to
increased vascular permeability. Secondly, through the
increase of pro-inflammatory mediators that leads to uti-
lisation of immune cells such as macrophages in their
response to wound mode. Thirdly, through the generation
of other factors which promote cell growth, angiogenesis
and matrix synthesis. The observation that cancer resem-
bles a wound that never heals is therefore substantiated.
Confirming the systemic role of the AT1 receptor in 
inflammation and disease
With the role of AT1 in cancer established, when the liter-
ature of other diseases is reviewed, it is reasonable to
anticipate that the role of this receptor is system-wide with
regard to inflammation. Interest in the wider implications
of the AT1 receptor within disease is gradually increasing
and these studies further substantiate a systemic role for
AT1 as a key inductor of inflammation and disease. In
these studies, a wide variety of pro-disease mediators,
such as TNF-α, NFκB, IL-6, TGF-β, surface adhesionJournal of Inflammation 2004, 1:3 http://www.journal-inflammation.com/content/1/1/3
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molecules and PAI-I are shown to be induced by AT1
(Table 1).
It is clear that a number of diseases, including heart and
kidney disease, diseases associated with the liver and pan-
creas, as well as diseases of the skin, bone, the brain and
most of the autoimmune and inflammatory disorders, are
all affected by the AT1 blockade. It is worth noting at this
stage that many of these diseases are often considered to
be associated with ageing and with fibrosis. An investiga-
tion of the action of IGF-1 in the regulation of expression
of AT2 leads to an explanation of this association.
Role of IGF-1 in regulating AT receptors
The majority of studies on AT1 are related to cardiovascu-
lar disease, for which AT1 receptor antagonists were gen-
erated as treatment. Regarding AT2, although there has
been increased research and interest in its role, this area
appears little explored. That which has been learnt so far
about the interplay and regulation of these receptors lends
itself to a potentially useful model for the management of
inflammation:
The expression of AT1 and AT2 receptors on fibroblasts
present in cardiac fibrosis is investigated [79]. These types
of fibroblast are noted for their expression of AT1 and AT2
receptors. The presence of IL-1b, TNF-α and lipopolysac-
charides, through induction of NO and cGMP, all serve to
down-regulate AT2 with no effect on AT1 leading to a
quicker progression of fibrosis. Interestingly, the continu-
ance in the presence of pro-inflammatory signals serves to
delay expression of AT2. This is confirmed in a separate
AT1 signalling Figure 2
AT1 signalling. Activation of AT1 has a powerful pro-inflammatory effect, promoting the expression of many pro-inflamma-
tory mediators, such as cytokines, chemokines and adhesion molecules through the activation of signalling pathways. The influx, 
proliferation and behaviour of immune cells are steered away from an effective immune response to pathogens (thereby 
achieving immunosuppression) but instead towards activities consistent with a wound environment.Journal of Inflammation 2004, 1:3 http://www.journal-inflammation.com/content/1/1/3
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local effects of AT1 activation Figure 3
local effects of AT1 activation. Activation of AT1 leads to growth factors causing increased vascular permeability, pro-
inflammatory mediators that lead to utilisation of immune cells such as macrophages in their response to wound mode and 
other factors that promote cell growth, angiogenesis and matrix synthesis during fibrosis and resolution.
Table 1: AT1 as a key inductor of inflammation and disease. A wide range of pro-inflammatory mediators, cytokines, chemokines and 
surface adhesion moleculesinvolved in a number of diseases are induced by AT1 and thus inhibited by its blockade.
Disease Mediators inhibited by AT1 blockade Reference
Cardiovascular disease NFκB, 'markers of oxidation inflammation and fibrinolysis' 66
Cardiovascular disease TGF-β 67
Cardiovascular disease TNF-α, IL-6, ICAM-1, VCAM-1 18
Cardiovascular disease PAI-1 19
Cardiovascular disease Surface adhesion molecules 68,69
Cardiovascular disease MCP in Hypercholesterolemia associated endothelial dysfunction 70
Kidney disease None noted in this study. 71
Pancreatitis (Key markers of the disease) 72
Liver fibrosis and cirrhosis 'TGF-β and pro-inflammatory cytokines' 21
Skin disease None noted in this study. 73
Osteoporosis 'Markers of inflammation' 74
Alzheimer's, Huntington's and Parkinson's (TGF-β [75], over expression of AT1 and AT2 noted in affected brain areas) 75–78Journal of Inflammation 2004, 1:3 http://www.journal-inflammation.com/content/1/1/3
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study of AT2 expression in proliferating cells. TGF-β1 and
bFGF are shown as powerful inhibitors of AT2 expression,
whilst IGF-1 is shown to induce the expression of AT2
[80].
IGF-1 is principally produced by the liver from GH
(Growth Hormone) and circulates in the blood (decreas-
ing with age) and is important in the regulation of immu-
nity and inflammation [81]: IGF-1 is also capable of being
produced by fibroblasts and macrophages on induction
by pro-inflammatory cytokines, including TNF-α and IL-
1b. In addition to the induction of AT2, IGF-1 can be seen
as responsible for mediating the actions of many active
cells in the immune/inflammation response [81]. Of note
is that TNF-α and IL-1b also affect the circulating expres-
sion of IGF-1 by feedback on the release of GH from the
anterior pituitary.
The controlling role of AT receptors in inflammation and 
healing
Significant evidence has been shown that AT1 receptors
are upregulated during disease and that AT2 receptor
expression follows behind AT1 expression during injury
and healing. Given the opposing roles of AT1 and AT2 it
can thus be postulated that the interplay of these receptors
plays a significant part in judging the current local status
of appropriate versus inappropriate inflammation and in
providing feedback to the rest of the body. Indeed it is
anticipated that prolonged expression of AT1 combined
with a lack of AT2 expression results in sustained chronic
inflammation and fibrosis.
Overall, the role of the AT receptors in managing and
monitoring the healing process is complex, with many
positive and negative feedback mechanisms both within
the site of inflammation/healing and with the rest of the
systems in the body. An attempt to summarise these
systemic signalling inter-relationships is given in figure 4.
Note the glucocorticoid inhibition of AT1 pro-inflamma-
tory activities via NFκB. This model, although hypotheti-
cal, provides an explanation of the mechanisms whereby
ox-LDL and homocysteine exert their pro-inflammatory
effects. Further supporting this model is evidence that a
lack of IGF-1 presence contributes to degenerative arthritis
[81], septic shock [81], cardiovascular diseases [82] and
inflammation of the bowel [83]. The introduction of IGF-
1 is also proposed for protection against Huntington's
[84], Alzheimer's [85] and Parkinson disorders [86].
Upregulation of IGF-1 has been noted in patients with
chronic heart failure who undertake a programme of
stretching exercise, thus providing benefits against cardiac
cachexia [87].
Conclusions
The invasiveness and immunosuppression of many can-
cers appears dependent on inflammation and the upregu-
lation of AT1. Two mechanisms for upregulation of AT1
are discussed: 1) evolutionary changes to take advantage
of this pro-inflammatory control mechanism, 2) AT1
expression induced by an alternating environment of
hypoxia and oxidative stress. Immunosuppression as a
common protection mechanism of solid tumours against
immune responses has been verified from current litera-
ture and experimental procedures, as has the implication
of cytokines and chemokines in tumour growth and
metastasis. Given the involvement of AT1 in the immuno-
suppression and inflammatory processes, as well as in the
expression of the pro-inflammatory cytokines and chem-
okines, it becomes evident that the AT1 receptor is essen-
tial for tumour protection and progression. A
combination therapy consisting of AT1 receptor antago-
nists, NSAID for further control of the inflammation and
immune therapy in the form of tumour vaccines should
provide a novel and successful treatment for solid
tumours.
In the renin-angiotensin system, the angiotensin II recep-
tors AT1 and AT2 seem to have opposing functions. The
actions of AT1 being principally pro-inflammatory whilst
AT2 provides protection against hypoxia, draws
inflammatory action to a close and promotes healing. The
various direct and indirect mechanisms for feedback
between the receptors, their induced products and the
external hormonal system in the control of inflammation
and healing are summarised in a highly simplified model
which none the less can be used to explain how many key
promoters and inhibitors of disease exert their effects.
From a review of the current disease literature, it has been
demonstrated that the role of AT1 and AT2 in
inflammation is not limited to cancer-associated inflam-
mation, but is generally consistent and system wide.
Potential therapy by manipulation of these receptors,
although at an early stage, has been demonstrated for
some of these diseases and it is proposed that this
approach will provide an effective basis for the treatment
of autoimmune, inflammatory and neurodegenerative
disorders using existing drugs. AT1 receptor blockade
should, in addition, provide a treatment to alleviate the
damage caused by bacterial and viral infections, where
their destructive action is through chronic inflammation.
Given the importance of the immune suppressant effect of
inflammation in cancer, it is anticipated that AT1 block-
ade should also serve to elicit a more effective immune
response to other invaders that seek to corrupt the wound
recovery process.
Manipulation of the AT1 and AT2 receptors has profound and exciting implications in the control of disease.Journal of Inflammation 2004, 1:3 http://www.journal-inflammation.com/content/1/1/3
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List of abbreviations used
TGF-β Transforming Growth Factor Beta
AT1 Angiotensin II Type 1 receptor
AT2 Angiotensin II Type 2 receptor
IGF-1 Insulin-like Growth Factor 1
LOX-1 Lectin-like Oxidized Low-Density Lipoprotein
Receptor 1
HIF-1a Hypoxia Induced Factor 1 Alpha
HMG CoA 3-Hydroxy-3-Methyl-Glutaryl Coenzyme A
bFGF basic Fibroblast Growth Factor
ROS Reactive Oxygen Species (most notably O2
-.)
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